| Authors: |
Mason B; Adelphi Values Patient-Centered Outcomes, Bollington, UK. brad.mason@omc.com., Eccleston A; Pfizer Inc., Surrey, UK., Ayala-Nunes L; Adelphi Values Patient-Centered Outcomes, Bollington, UK., Hauber B; Pfizer Inc., New York, NY, USA., Gater A; Adelphi Values Patient-Centered Outcomes, Bollington, UK., Coulter J; Pfizer Inc., New York, NY, USA., Hallworth P; Adelphi Research, Bollington, UK., Thompson A; Pfizer Inc., New York, NY, USA., Bell B; Adelphi Research, Bollington, UK., Chang J; Pfizer Inc., New York, NY, USA., Brinkmann J; Pfizer Pharma GmbH, Friedrichstrasse 110, 10117, Berlin, Germany., Cappelleri JC; Pfizer Inc., Groton, CT, USA., Chisolm S; Bladder Cancer Advocacy Network (BCAN), Bethesda, MD, USA., Satkunasivam R; Department of Urology, Houston Methodist Hospital, Houston, TX, USA. |